Objective: To evaluate immediate and long-term clinical outcomes of stenting for middle aortic syndrome (MAS) caused by Takayasu arteritis (TA).
obstructive dissection and long-term patency along with PTA alone still exist [12, 13] . Hence, some case reports [14, 15] and retrospective studies [12, 13] evaluated the feasibility of stenting for the treatment of this condition. However, related data are quite limited, and the clinical outcomes of this treatment strategy have not been systematically evaluated in relatively large sample sizes. In light of these factors, we reported our experience with endovascular stenting for the treatment of patients with MAS due to TA admitted to our center during the past 7 years.
| M A TE RI A L S A ND M E TH ODS

| Study population
Between January 2010 and July 2016, 48 consecutive patients with MAS caused by TA who underwent aorta stenting were included in our institution. All patients were classified as TA according to the criteria of the American College of Rheumatology [16] . MAS was diagnosed as stenosis or occlusion in the distal thoracic or abdominal aorta by CT angiography or aortography. Aortic stenosis was defined as a diameter reduction 50% from the thoracic aortic isthmus to the end of abdominal aorta by aortography. Indication for aorta stenting was defined as aorta diameter reduction of 70% accompanied by lower limb claudication, hypertension, or left ventricular dysfunction. Exclusion criteria included (1) intolerance to heparin or antiplatelet drugs; (2) aorta aneurysms or dissection; (3) severe renal insufficiency (GFR < 30 ml/min); (4) allergy to iodinated contrast agent; and (5) life expectancy < 2 years.
According to the angiographic classification proposed by Takayasu's Consensus Conference in 1994 [17] , TA was classified as follows: type I with the involvement of the aortic arch and its major branches; type IIa affecting the ascending aorta, aortic arch and its branches; type IIb involving the ascending aorta, aortic arch with its branches and thoracic descending aorta; type III with a lesion of the thoracic descending aorta, abdominal aorta and/or renal arteries; type IV with only the abdominal aorta and/or renal arteries involved; and type V having combined features of both type IIb and IV.
The protocol was approved by the ethics committee of our hospital, and written informed consent was obtained from each patient before the procedure.
| Interventional procedure and medical protocol
Before the procedure, all patients received aspirin (100 mg/d) and clopidogrel (75 mg/d) for at least 2 days plus a loading dose of clopidogrel (150 mg) if patient had not previously been receiving clopidogrel.
Aortography was routinely performed via the femoral artery except in patients with aorta occlusion. Using the Seldinger technique, an 8F introducer sheath was positioned, and a bolus of 50 U/kg unfractionated heparin was injected intra-arterially. Then, a 5F pigtail diagnostic catheter was advanced into the aortic isthmus over a 0.035-inch, 260-cm-long super slide guidewire (HiWire, Cook Medical, Bloomington, Indiana). Angiography of the thoracic aorta and abdominal aorta were performed consecutively. The location, degree, length of the stenosis, and the trans-stenotic peak systolic pressure gradient (PSG) were measured and recorded; digital subtraction angiography was used to acquire a high-quality image.
The diagnostic catheter was then removed while the hydrophilic guidewire was maintained in the aorta. An 8F MPA1 guiding catheter (Boston Scientific, Natick, Massachusetts) was inserted into the aorta over the hydrophilic guidewire. The lesion was first predilated by graded undersized balloons with a maximal size 80% of the original size of the aorta diameter. An appropriately sized self-expanding stent (e.g., Wallstent, Boston Scientific) was positioned across the angioplasty site over the super slide guidewire. Stent diameter and length were selected depending on the measurement of the stenotic segment on the angiographic image. Stent diameters ranged from 14 to 24 mm, and the length was from 40 to 70 mm. After the stent was inserted, the PSG was measured once again, and a check aorta angiogram was obtained ( Figure 1 ). When the residual stenosis was 30%, postdilation with a larger balloon was considered. After the procedure, the femoral sheath was removed, and local hemostasis was achieved with an 8F Angio-seal device.
Medication therapy including prednisone and immunosuppressive agents were administered during the perioperative period and at follow-up. Prednisone was commenced at a daily dose of 0.5 mg/kg for 1 month after stenting and tapered to a maintenance dosage of 5-10 mg per day gradually to maintain normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). In our experience, this helped to prevent recurrent inflammation and in-stent restenosis (ISR). Antihypertensive medication was adjusted according to blood pressure level after discharge. Dual antiplatelet therapy was continued for at least 1 month, and aspirin was continued for at least 6 months.
| End points and follow-up
Clinical follow-up visits were advised at 1, 3, 6, and 12 months after aorta stenting and every year thereafter to evaluate the symptoms, blood biochemical parameters, blood pressure, ankle-brachial index (ABI), echocardiography, New York Heart Association (NYHA) functional class and adverse events by a dedicated research coordinator. All patients were required to receive computerized tomographic aorta angiography at 6 months after the stenting and at any time when ISR was suspected to assess the patency. Repeat aorta angiography was advised if any patient had symptomatic ISR.
Increases in levels of inflammatory markers were defined according to local laboratory standard reference ranges. The ESR reference value was < 20 mm/h in women and < 15 mm/h in men based on the Westergren method. CRP reference value was 0-8 mg/l. ISR was defined as an increase in stenosis 50% during follow-up.
Target vessel revascularization (TVR) was defined by a repeat intervention of the target lesion in patients with ISR.
| Statistical analysis
Continuous variables were expressed as the mean values 6 standard deviation. Categorical variables were expressed as the counts (percentage). Variables before and after stenting or between thoracic aortic stent group and abdominal aortic stent group were compared using the paired t-test and independent-sample t-test, respectively. A P value < .05 was considered statistically significant, and all reported p values were two-sided. Statistical analysis was performed using SPSS software (version 19.0, SPSS Inc., Chicago, Illinois). Table 1 shows the characteristics of the patients at baseline. The mean age at disease onset was 27.4 6 11.2 years, with a female-to-male ratio of 4.3:1. According to classification criteria, the most common type of TA was type V (21, 43.8%), followed by type III (15, 31.3%), type IIb (9, 18.8%), and type IV (3, 6.3%). For vascular involvement other than the aorta, the most frequently affected artery was the left subclavian artery (17, 35.4%).
Involvement of 3 or 4 of the supra-arch arteries was observed in 14 patients (29.1%).
At the time prior to aorta stenting, the ESR in men and women was 7.8 6 10.0 mm/h and 10.5 6 9.7 mm/h, respectively, with a mean 10.0 6 9.9 mm/h overall. The CRP level was 5.6 6 8.3 mg/l. Increased levels of the inflammatory markers of ESR and CRP were observed in 3 and 2 patients, respectively. Anti-inflammatory therapy before the procedure consisted of corticosteroids in 46 of the 48 patients (95.8%) and immunosuppressants in 7 (14.6%), including cyclophosphamide (n 5 5), methotrexate (n 5 1), and azathioprine (n 5 1).
| Interventional-related data
Detailed interventional-related data are shown in Table 2 . Recanalization of the lesions was successful in all 48 patients (100%). Lesions were located suprarenal, interrenal or infrarenal in 36 (75.0%), 5 (10.4%), and 7 (14.6%) patients, respectively. The mean stenosis of lesions and PSG were reduced from 81.3 6 8.0% (range, 70-100%) and 70.7 6 18.4 mm Hg (range, 50-110 mm Hg) to 14.7 6 8.3% (range, 0-30%) and 14.0 6 5.8 mm Hg (range 5-40 mm Hg) immediately after 54 stents were implanted (both P < .001). Other artery involvement with stenosis 50% were primarily found in the subclavian artery (26, 54.2%), carotid artery (18, 37.5%), and renal artery (20, 41.7%), in which 10 patients (50%) received simultaneous renal artery intervention.
| Thirty-day adverse events
At 30 days post procedure, there were no catheter-related deaths. One patient had a long, diffuse stenosis in the abdominal aorta with severe hypertension and developed flow-limiting dissection involving bilateral renal arteries after predilation with a 10-mm balloon. The dissection resolved after two 14*40 mm self-expandable stents were inserted, however, the left renal artery was occluded with only micro blood-flow remaining. The patient partially recovered after left renal artery angioplasty and was discharged 10 days later. The other patient developed a retroperitoneal hemorrhage at the puncture site during the procedure that was detected after the abdominal aortic stent was implanted. The bleeding was stopped by sustained balloon compression and the patient completely recovered 15 days after the procedure. Another patient developed a puncture site arteriovenous aneurysm that resolved after manual compression. Other adverse events were not observed. The rate of short-term (30 days) complications was 6.3% (3/48).
| Follow-up
Two patients were lost to follow-up after being discharged from our hospital. Clinical follow-up was obtained in the remaining patients at a patients received PTA alone) (Figure 2 ).
| Analysis between thoracic aorta and abdominal aorta
When the patients were divided into two groups (thoracic aorta and abdominal aorta) according to the location of the most stenotic lesion, we found that the lesion length of the thoracic aorta was shorter than that of the abdominal aorta (30.0 6 13.6 vs. 39.4 6 7.3, P 5 .010), whereas the degree of stenosis in the thoracic aorta was more severe (83.5 6 7.0% vs. 77.6 6 8.4%, P 5 .012) with a more significant PSG (74.6 6 15.2 mm Hg vs. 64.2 6 8.7 mm Hg, P 5 .004) than that in the abdominal aorta. Other details are shown in Table 4 . During the followup period, the overall improvement of the thoracic aorta group was better than that of the abdominal aorta group including for stenosis degree, PSG, and blood pressure level (Table 4) .
| D ISC USSION
TA is a chronic vasculitis that primarily affects the aorta and its branches and predominantly manifests as stenotic arterial lesions.
Endovascular stenting for the treatment of MAS caused by TA has rarely been reported. To the best of our knowledge, the present study and complexity of structure changes in the wall of the aorta [18, 19] .
According to the results of Pokrovsky's research [20] , the mortality rate and early postoperative complication rates were 13% and 14%, respectively, including hemorrhage at the anastomotic site and acute thrombosis as well as a 24% incidence of graft occlusion during follow-up recorded by Giordano [21] . Due to these factors, reconstructive surgery has not been widely used.
With recent tremendous advances in endovascular therapy, PTA and stenting for stenotic TA lesions of the aorta and its branches have been reported to show excellent immediate and long-term results when compared with surgical procedures [8, 18, 22] . However, this form of therapy has been reported in only a few cases [14, 15] and small retrospective [12, 13] studies with aorta involvement. Initially, patients with stenotic lesions of the aorta typically received PTA alone. In the study conducted by Tyagi [11] , 34 patients successfully underwent PTA. The mean PSG was decreased from 75.2 6 29.1 mm Hg to 24.8 6 19 mm Hg (P < .001), and the diameter of the stenotic segments increased from 4.5 6 2.2 mm to 9.6 6 3.8 mm (P < .001). Gu et al. [10] reported that all 7 patients were free of symptoms from the lower extremities and that blood pressure decreased significantly in hypertensive cases after PTA of the abdominal aorta during 3 to 28 months follow-up.
However, in patients with TA, the affected aorta always resisted prolonged and repeated mechanical distension before responding to PTA due to its tough, rigid and noncompliant vessel walls caused by the disease characteristics. Moreover, flow-limiting dissection may develop in TA patients who undergo an aorta angioplasty alone and the eccentric stenosis, calcification and diffused lesion will adversely affect the results of PTA due to large intimal flaps [10, 12] . Therefore, Saadoun et al. [18] concluded that the overall 5-year arterial complication rate for patients with TA was 44%, and increased biological inflammation markers at the time of revascularization were associated with a higher (7-times) incidence of increased complications. In our study, all patients underwent intervention therapy with stable disease for at least 2 months except patients who required more urgent intervention. The ESR and CRP were 10.0 6 9.9 mm/h and 5.6 6 8.3 mg/l, respectively, and only five patients had slight elevations in inflammation markers at the time of stenting, which may reflect our better safety outcome in comparison with previously published studies [18] .
In the present study, one retroperitoneal hemorrhage and one Some researchers have raised concerns about the long-term behavior of intimal hyperplasia and the response of a stented aorta to the natural aging process in young patients. However, surgical reconstruction also confronts this problem regarding the anastomotic site.
Additionally, 46 patients (95.8%) were over 18 years old in our study.
Two patients were 15 and 17 years old, respectively, and we believe that they had well-developed aortas. The mean age of the patients in our study was 33.3 years, which was much "older" than patients described previously [10] [11] [12] , so such concerns were reduced in our study.
One patient developed flow-limiting dissection involving the bilateral renal artery during the perioperative period. This could have been due to her long, diffuse, fibrotic, and significantly stenotic aorta lesions, which always requires a higher balloon dilation pressure, leading to iatrogenic vascular injury. The injury then left the left renal artery covered by large intimal flaps. A similar experience was also reported by Sharma in which PTA resulted in an obstructive dissection in all four patients.
Therefore, we suggested that overdilation with large balloons should be avoided, and the balloons that are used should be long enough to cover the whole stenotic lesion. Otherwise, balloon angioplasty may result in dissection or even rupture of the aorta.
Our study was limited by its noncontrolled single-center retrospective study nature, which made a direct comparison with other treatment methods (e.g., surgery) impossible. Moreover, although our study was the largest cohort study of TA patients along with MAS, only 48 patients received endovascular stenting. Prospective randomized trials comparing with surgical operation are needed in the future in larger sample sizes.
In conclusion, stenting for MAS caused by TA was safe and provided acceptable long-term patency. Subjective symptoms and objective variables were improved significantly immediately after stenting and maintained for 3.1 years of follow-up. Thoracic aorta lesions in TA were more likely to obtain better improvement after aorta stenting in comparison with TA involving the abdominal aorta.
DE CL A RA TI ON OF I NT ER EST
None.
